In 2023, Novartis completed its transformation into a “pure-play” innovative medicines business. We have a clear focus onfour core therapeutic areas(cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple signifi...
(<5kg patients) News update – CHMP positive opinion – US submission, priority review granted – Submission using MAGHP procedure in Switzerland to facilitate rapid approvals in developing countries Selected Innovative Medicines pipeline projects Compound/ product Potential indication/ Disease area First ...
6月12日,Novartis公告拟以35亿美元总价款收购Chinook Therapeutics,重点瞄准了旗下两款用于治疗IgA肾病的分子。 https://www.novartis.com/news/media-releases/novartis-bolsters-innovative-medicines-strategy-and-renal-pipeline-agreement-...
In 2023, Novartis completed its transformation into a “pure-play” innovative medicines business. We have a clear focus onfour core therapeutic areas(cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple signifi...
(iptacopan) hemoglobinuria Xolair Food allergy Q4 2023 News update – US filing – US approval – Genentech submission Selected Innovative Medicines pipeline projects Compound/ product Potential indication/ Disease area First planned submissions Current Phase News update Aimovig Migraine, pediatrics ≥2027...